News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A 7+% gain on share price this AM. News says it might be an acquisition target.
https://www.barrons.com/articles/boston-scientific-edwards-lifesciences-may-tempt-j-j-1537575592?siteid=yhoof2&yptr=yahoo
It's trading well above its previous 52 week high.
It's been a while since I updated my EW position history. This histogram shows where it's been since the start in 2014 and updates what's happened since about a year ago:
I was lucky to cut overall risk exposure when I did as those funds were used to supplement other positions in a 10 stock portfolio. It's taken until just the last month or so for the stock to rise above that same price/share. Those opportunistic buys I made back under $100/share now look pretty good.
Value Line now gives EW a 3-5 year price target of between $160 and $245. It's still ranked A+ for financial strength with price growth persistence at 80 (5 to 100 range) and stock price stability of 45 (5 to 100 range).
Hi P, Re: Long term with EW.............
2014 was when I first added EW to my portfolio at around $36 (split adjusted). So, it's done well for me. Last Sept I reduced my overall holding in EW by around 50% because of it becoming overweight in that 10 stock portf. That was at around $116/sh.
About a month later it dropped back to $93 and I added back some shares. It continued down and I managed to add more shares at around $85/share.
(Stacked Bar Histogram: Red on bottom is cash in reserve, Green is the stock value)
It's again starting to throw off some cash for me with a sale of 10% of the shares at around $110/sh. I need an additional +10% added to the price before I'll again take some off the table.
This week's newest EW report from Value Line has raised its "Timeliness" rank to 2 with a 3-5 year "appreciation potential" target of $150 to $220/share. It also remains on their "Highest Growth Stocks" list (Page 39 of the Summary and Index section). It carries a VL Financial Strength rank of A+ (second highest).
It has a "Price Growth Persistence" rank of 80 (5 to 100 range) but carries a "Stock Price Stability" rank of 35 (5 to 100 range). So, it would appear it has a long term upward trend with hick-ups along the way. I've been trading the hick-ups while enjoying the long term growth.
I, too, am surprised it doesn't have much following here.
5yr DCF imply Edwards Lifesciences $EW has 9% upside before earnings Wednesday:
DCF Analysis
EW DAY
fantastic move this morning..........
best, jeff
not sure about that, EW has a 50/200ema crossover approaching, if it
breaks up thru $73 and closes above, my guess EW can almost run to $100
by this summer, I'll wait till the chart tells me otherwise...................good luck
Edwards Life Sciences u[graded this morning to Outperform by Wells Fargo
no price target but i notice a lot of insider sells lately from option exercise....
looks like EW on a upward trajectory for now, maybe get to $100
TAVI: Mixed results for Edwards' Sapien valve in latest Partner analysis
https://www.massdevice.com/news/tavi-mixed-results-edwards-sapien-valve-latest-partner-analysis
Edwards Lifesciences (NYSE:EW) reported EPS of $0.58 in the third quarter of 2012, surpassing the Zacks Consensus Estimate by $0.02. Sales increased 8.5% to $447.9 million, in line with the preliminary result but lagged the original guidance of $465-$485 million. This was primarily due to lower-than-expected THV sales due to economic uncertainties in Europe, coverage issues for certain inoperable patients in US and later-than expected approval of Sapien in high-risk patients.
Given these headwinds, the company lowered its outlook for 2012. We prefer to avoid the stock and accordingly downgrade it to Underperform.
Edwards current trailing 12-month earnings multiple is 36.3. The stock is currently trading at 27.1x the 2013 EPS estimate of $3.21. Our target price is based on 24.6x our 2013 EPS estimate.
there is interest,we just keep to ourselves, ihub message boards
for penny fluffers.....................
best
well, time to buy EW???????????
EW, another guidance hit
Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."
AI
